Yanxia Ning1, Jin Kyung Kim1, Hae-Ki Min1, Shunlin Ren2. 1. Department of Internal Medicine, Virginia Commonwealth University/McGuire Veterans Affairs Medical Center, Richmond, VA 23249, United States. 2. Department of Internal Medicine, Virginia Commonwealth University/McGuire Veterans Affairs Medical Center, Richmond, VA 23249, United States. Electronic address: shunlin.ren@vcuhealth.org.
Abstract
BACKGROUND: Oxysterol sulfation plays a fundamental role in the regulation of many biological events. Its products, 25-hydroxycholesterol 3-sulfate (25HC3S) and 25-hydroxycholesterol 3, 25-disulfate (25HCDS), have been demonstrated to be potent regulators of lipid metabolism, inflammatory response, cell apoptosis, and cell survival. In the present study, we tested these products' potential to treat LPS-induced acute liver failure in a mouse model. METHODS: Acute liver failure mouse model was established by intravenous injection with LPS. The injured liver function was treated with intraperitoneal administration of 25HC, 25HC3S or 25HCDS. Serum enzymatic activities were determined in our clinic laboratory. ELISA assays were used to detect pro-inflammatory factor levels in sera. Western blot, Real-time Quantitative PCR and RT2 Profiler PCR Array analysis were used to determine levels of gene expression. RESULTS: Administration of 25HC3S/25HCDS decreased serum liver-impaired markers; suppressed secretion of pro-inflammatory factors; alleviated liver, lung, and kidney injury; and subsequently increased the survival rate in the LPS-induced mouse model. These effects resulted from the inhibition of the expression of genes involved in the pro-inflammatory response and apoptosis and the simultaneous induction of the expression of genes involved in cell survival. Compared to 25HC, 25HC3S and 25HCDS exhibited significantly stronger effects in these activities, indicating that the cholesterol metabolites play an important role in the inflammatory response, cell apoptosis, and cell survival in vivo. CONCLUSIONS: 25HC3S/25HCDS has potential to serve as novel biomedicines in the therapy of acute liver failure and acute multiple organ failure. Published by Elsevier Inc.
BACKGROUND:Oxysterol sulfation plays a fundamental role in the regulation of many biological events. Its products, 25-hydroxycholesterol 3-sulfate (25HC3S) and 25-hydroxycholesterol 3, 25-disulfate (25HCDS), have been demonstrated to be potent regulators of lipid metabolism, inflammatory response, cell apoptosis, and cell survival. In the present study, we tested these products' potential to treat LPS-induced acute liver failure in a mouse model. METHODS:Acute liver failuremouse model was established by intravenous injection with LPS. The injured liver function was treated with intraperitoneal administration of 25HC, 25HC3S or 25HCDS. Serum enzymatic activities were determined in our clinic laboratory. ELISA assays were used to detect pro-inflammatory factor levels in sera. Western blot, Real-time Quantitative PCR and RT2 Profiler PCR Array analysis were used to determine levels of gene expression. RESULTS: Administration of 25HC3S/25HCDS decreased serum liver-impaired markers; suppressed secretion of pro-inflammatory factors; alleviated liver, lung, and kidney injury; and subsequently increased the survival rate in the LPS-induced mouse model. These effects resulted from the inhibition of the expression of genes involved in the pro-inflammatory response and apoptosis and the simultaneous induction of the expression of genes involved in cell survival. Compared to 25HC, 25HC3S and 25HCDS exhibited significantly stronger effects in these activities, indicating that the cholesterol metabolites play an important role in the inflammatory response, cell apoptosis, and cell survival in vivo. CONCLUSIONS:25HC3S/25HCDS has potential to serve as novel biomedicines in the therapy of acute liver failure and acute multiple organ failure. Published by Elsevier Inc.
Authors: John Eppensteiner; Jean Kwun; Uwe Scheuermann; Andrew Barbas; Alexander T Limkakeng; Maggie Kuchibhatla; Eric A Elster; Allan D Kirk; Jaewoo Lee Journal: JCI Insight Date: 2019-08-22
Authors: Lei Feng; Lei Cai; Guo-Lin He; Jun Weng; Yang Li; Ming-Xin Pan; Ze-Sheng Jiang; Qing Peng; Yi Gao Journal: World J Gastroenterol Date: 2017-11-14 Impact factor: 5.742
Authors: Hamideh Parhiz; Jacob S Brenner; Priyal N Patel; Tyler E Papp; Hamna Shahnawaz; Qin Li; Ruiqi Shi; Marco E Zamora; Amir Yadegari; Oscar A Marcos-Contreras; Ambika Natesan; Norbert Pardi; Vladimir V Shuvaev; Raisa Kiseleva; Jacob W Myerson; Thomas Uhler; Rachel S Riley; Xuexiang Han; Michael J Mitchell; Kieu Lam; James Heyes; Drew Weissman; Vladimir R Muzykantov Journal: J Control Release Date: 2021-12-23 Impact factor: 11.467